Friday night before a long weekend, so you know what that means: time to dig through the SEC filings to find the interesting nuggets. Read on! You'll see that not everything is bad news...
Alimera Sciences $ALIM amends the terms of their loan.
Bellorophon Therapeutics $BPLH enters into ATM agreement.
Celyad $CYAD reports on T-cell therapy safety data.
Harvard Biosciences $HBIO amends executive employment agreements.
Intellipharmaceutics $IPCI selling stock and warrants.
Lion Biotechnologies $LBIO Chief Scientific Officer resigns.
Loxo Oncology $LOXO has an 18.6% owner after recent financing.
Medivation $MDVN responds to Sanofi's attempt to replace board of directors $SNY
Osiris Therapeutics $OSIR discloses criminal investigation.
Proteostasis Therapeutics $PTI rejiggers Astellas collaboration and signs a lucrative consulting deal with none other than Stelios Papadopoulos! Intriguingly, the terms of the agreement includes a bonus worth 1% of the value of any successful M&A deal...
Raptor Pharmaceutical Corp $RPTP moves their annual meeting to November.
TrovaGene $TROV files $250m shelf.
Bellorophon Therapeutics $BPLH enters into ATM agreement.
Celyad $CYAD reports on T-cell therapy safety data.
Harvard Biosciences $HBIO amends executive employment agreements.
Intellipharmaceutics $IPCI selling stock and warrants.
Lion Biotechnologies $LBIO Chief Scientific Officer resigns.
Loxo Oncology $LOXO has an 18.6% owner after recent financing.
Medivation $MDVN responds to Sanofi's attempt to replace board of directors $SNY
Osiris Therapeutics $OSIR discloses criminal investigation.
Proteostasis Therapeutics $PTI rejiggers Astellas collaboration and signs a lucrative consulting deal with none other than Stelios Papadopoulos! Intriguingly, the terms of the agreement includes a bonus worth 1% of the value of any successful M&A deal...
Raptor Pharmaceutical Corp $RPTP moves their annual meeting to November.
TrovaGene $TROV files $250m shelf.
RSS Feed
